MaxCyte, Inc. (AIM:MXCT)
320.00
-5.00 (-1.56%)
Feb 21, 2025, 4:35 PM GMT+1
MaxCyte Employees
MaxCyte had 143 employees as of December 31, 2023. The number of employees increased by 18 or 14.40% compared to the previous year.
Employees
143
Change (1Y)
18
Growth (1Y)
14.40%
Revenue / Employee
237.91K GBP
Profits / Employee
-186.45K GBP
Market Cap
338.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Genus | 3,500 |
MaxCyte News
- 11 days ago - MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - Seeking Alpha
- 11 days ago - MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - GlobeNewsWire
- 16 days ago - MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - GlobeNewsWire
- 23 days ago - Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire
- 24 days ago - MaxCyte acquires SeQure Dx - Seeking Alpha
- 24 days ago - MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - GlobeNewsWire
- 5 weeks ago - MaxCyte estimates higher Q4 core revenue from last year - Seeking Alpha
- 5 weeks ago - MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire